Toremifene--a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy

Expert Opinion on Investigational Drugs
Samir S TanejaKaren A Veverka

Abstract

Deregulation of the estrogen axis in humans prompts a series of tissue-specific events. In the breast and prostate, alterations in estrogen signalling lead to genotypic and phenotypic molecular alterations that result in dysplastic cellular appearance, deregulated cell growth and carcinoma. In bone, decreased estrogen leads to increased osteoclastogenesis and bone resorption, decreased bone mineral density and a significant fracture risk. Toremifene is a selective estrogen receptor modulator that exerts pharmacological activity in the breast, bone and prostate. An intense interest in developing this agent for prostate cancer chemoprevention is based on the reduction of premalignant and malignant prostate lesions in a transgenic model of prostate cancer. Biological and clinical activity was demonstrated in Phase II trials by the prevention of progression to prostate cancer in men with high-grade prostate intraepithelial neoplasia and through suppression of bone turnover biomarkers and increased bone mineral density in men on androgen deprivation therapy for prostate cancer.

References

Aug 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·M J OurslerT C Spelsberg
Jan 1, 1990·Cancer Chemotherapy and Pharmacology·V J WiebeM W DeGregorio
Jun 22, 1990·Journal of Steroid Biochemistry·H SipiläM Anttila
Jun 22, 1990·Journal of Steroid Biochemistry·M AnttilaJ Mäenpää
Jan 1, 1990·Cancer Chemotherapy and Pharmacology·L Kangas
Aug 1, 1990·Breast Cancer Research and Treatment·P C KohlerD C Tormey
Aug 1, 1990·Breast Cancer Research and Treatment·T TominagaY Nomura
Feb 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·D S ColvardT C Spelsberg
Jul 1, 1988·Pharmacology & Toxicology·H SipiläT Halme
Aug 1, 1995·Calcified Tissue International·S ErikssonK Carlström
Apr 11, 1995·Proceedings of the National Academy of Sciences of the United States of America·N M GreenbergJ M Rosen
Jun 1, 1995·Clinical Pharmacology and Therapeutics·M AnttilaE A Sotaniemi
Aug 1, 1993·Annals of Medicine·M J OurslerT C Spelsberg
Oct 24, 1997·Nature·A M BrzozowskiM Carlquist
Oct 29, 1997·Drugs & Aging·J U Mäenpää, S L Ala-Fossi
Apr 7, 1998·Molecular and Cellular Biology·J R WoodA M Nardulli
Oct 15, 1998·Cancer Chemotherapy and Pharmacology·G T WurzM W DeGregorio
Jan 1, 1999·Clinical Pharmacology and Therapeutics·K T KivistöP J Neuvonen
Jun 24, 1999·Molecular Endocrinology·T C SpelsbergS Khosla
Aug 30, 2000·Journal of the National Cancer Institute. Monographs·M C Bosland
Oct 14, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K HolliH Joensuu
Nov 1, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·R E HubbardM Carlquist
Nov 30, 2000·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·C G CarlsenE F Eriksen
Dec 7, 2000·Clinical Pharmacokinetics·T L TarasM W DeGregorio
Feb 13, 2001·The Journal of Steroid Biochemistry and Molecular Biology·B S KatzenellenbogenJ A Katzenellenbogen
Mar 30, 2001·The Journal of Biological Chemistry·M JakackaJ L Jameson
May 24, 2001·Proceedings of the National Academy of Sciences of the United States of America·Z WeihuaJ A Gustafsson
Jul 5, 2001·The American Journal of Pathology·S Signoretti, M Loda
Jul 27, 2001·The Breast Journal·B K Dunn, L G Ford

❮ Previous
Next ❯

Citations

Aug 15, 2006·Current Treatment Options in Oncology·Neil Fleshner, Girish Kulkarni
Mar 21, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M Dror MichaelsonMatthew R Smith
Nov 29, 2013·The Journal of Antimicrobial Chemotherapy·Nicolas DelattinKarin Thevissen
Aug 5, 2009·Expert Opinion on Emerging Drugs·Kashif Siddiqui, Laurence H Klotz
Sep 6, 2011·Endocrinology and Metabolism Clinics of North America·Shuk-Mei HoYuet-Kin Leung
Jun 29, 2010·Maturitas·James H PickarKathleen Ohleth
May 13, 2015·Biochimica Et Biophysica Acta·Samy A F Morad, Myles C Cabot
Mar 22, 2005·Theoretical Biology & Medical Modelling·A Edward Friedman
Aug 14, 2013·Biochimica Et Biophysica Acta·Samy A F MoradMyles C Cabot
May 10, 2013·PloS One·Simona NanniAntonella Farsetti
Jan 9, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Samir S TanejaMitchell Steiner
Jan 13, 2021·International Journal of Molecular Sciences·Jaqueline S da SilvaGisele Zapata-Sudo
Feb 19, 2008·Obstetrical & Gynecological Survey·Wendy ShellyRobert B Jaffe

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.